As Curemark is preparing to enter clinical trials for its proprietary drug for autism, Dr. Zinberg joins us at a most historic time
Rye, NY (PRWEB) September 23, 2008
Curemark is pleased to announce the appointment of Dr. Elisa J. Zinberg as Vice - President of Operations, and member of Curemark’s management team, effective immediately. Dr. Zinberg will be responsible for the day-to-day management of Curemark as well as for the implementation of Curemark’s strategic plan.
“In addition to having an outstanding track record in the health care field, Dr. Zinberg brings a tremendous level of expertise, energy and business acumen to Curemark,” states Dr. Joan Fallon, Curemark’s CEO. “We are honored to have someone of Dr. Zinberg’s caliber as Curemark’s new Vice–President of Operations.”
Dr. Zinberg was previously the Chief Operating Officer of a privately held multi-million dollar health care corporation, The Masters Circle. The Masters Circle provides consulting services to the health care sector within the United States and internationally.
“As Curemark is preparing to enter clinical trials for its proprietary drug for autism, Dr. Zinberg joins us at a most historic time,” states Dr. Matthew Heil, Vice-President for Drug Development and Manufacturing for Curemark. “She will help lead us into the next phases of our company development, and implementation of our strategic plan for our vast array of clinical targets.”
Curemark is a biotechnology company focused on the treatment of neurological and other diseases by addressing certain key gastrointestinal/pancreatic secretory deficiencies. The company’s initial products are based upon breakthrough observations by its founder, Dr. Joan Fallon. The company is currently preparing for clinical trials. To learn more about our innovative science, please visit: http://www.cure-mark.com.
info @ cure-mark.com